Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche develops new test kits for COVID-19 Omicron variant

12/03/2021 | 01:13am EST

ZURICH, Dec 3 (Reuters) - Roche's newly acquired subsidiary TIB Molbiol has developed three new tests kits to detect mutations present in the new COVID-19 Omicron variant, Roche said on Friday.

"The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour," Thomas Schinecker, head of Roche Diagnostics, said in a statement.

Roche acquired Berlin-based TIB Molbiol on Dec. 1 to expand its PCR-test portfolio to combat new infectious diseases. (Reporting by Brenna Hughes Neghaiwi Editing by Paul Carrel)


ę Reuters 2021
All news about ROCHE HOLDING AG
01/17ROCHE : virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting
PU
01/17ROCHE HOLDINGS AG : Buy rating from Deutsche Bank
MD
01/17GMP production of CG01 made available for preclinical studies planned to enable First i..
AQ
01/13ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
MD
01/12Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments
RE
01/12Oncolytics Biotech Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
AQ
01/12Roche launches the cobas« pulse system, an industry first professional blood glucose ma..
AQ
01/12Roche Launches Cobas Pulse System
CI
01/11U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients
RE
01/11Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional ..
AQ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 410 M 68 136 M 68 136 M
Net income 2021 15 291 M 16 694 M 16 694 M
Net Debt 2021 6 241 M 6 814 M 6 814 M
P/E ratio 2021 19,9x
Yield 2021 2,71%
Capitalization 295 B 322 B 322 B
EV / Sales 2021 4,83x
EV / Sales 2022 4,77x
Nbr of Employees 101 465
Free-Float -
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 364,90 CHF
Average target price 404,97 CHF
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-3.75%322 066
JOHNSON & JOHNSON-2.32%439 907
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992
NOVO NORDISK A/S-13.80%219 759